In this article
Topical finasteride has become a popular topic in hair loss, often as a spray mixed with minoxidil. Most of what you read online is about men. For women, the picture is different: the drug is not approved for you, the evidence is small, and there is one firm safety rule around pregnancy. This guide walks through what is known, what is not, and what to ask your clinician.
What finasteride is
Finasteride is a 5-alpha-reductase inhibitor. It blocks the enzyme that converts testosterone into dihydrotestosterone (DHT), a stronger androgen [1, 3]. Finasteride has been shown to be effective in men with pattern hair loss [3], and the tablets are FDA-approved for that use [1].
The approved label is direct: finasteride 1 mg is indicated for male pattern hair loss in men only and is not indicated for use in women [1]. When a clinician prescribes it to a woman, that is off-label use. Off-label means the drug has not been approved for that use, so there is no label written for women to guide dosing or safety.
Why might it help women at all? The role of androgens in female pattern hair loss is not well established [5]. A review of women's hair loss describes androgens as shrinking follicles by shortening the growth phase, and lists finasteride and dutasteride among off-label anti-androgen options [7]. Whether blocking DHT helps a given woman is exactly what the trials below tried to measure.
The pregnancy warning
Finasteride is contraindicated in women who are or may potentially be pregnant. Because it blocks the conversion of testosterone to DHT, it may cause abnormalities of the external genitalia of a male fetus [1].
The FDA label explains that DHT is necessary for normal development of male genitals, and that animal studies showed abnormal genital development in male fetuses [1]. It warns that women who are or may become pregnant should not even handle crushed or broken tablets, because finasteride can be absorbed through the skin [1]. Tablets are coated to prevent contact; the FDA notes that compounded topical finasteride products have no such coating [2].
This is why the research in women has focused on women after menopause. The authors of the main women's trial concluded that, because topical finasteride may be absorbed through the skin, it should be reserved for postmenopausal women [5]. If there is any chance you could become pregnant, tell your clinician before starting any finasteride product.
What oral finasteride showed in women
The best-known trial is older but important. In a one-year, double-blind trial, 137 postmenopausal women aged 41 to 60 with pattern hair loss took finasteride 1 mg or a placebo every day [3]. After a year, there was no significant difference in hair count between the groups, and photos, biopsies, and patient and investigator ratings showed no improvement with finasteride [3].
A Cochrane review of treatments for female pattern hair loss pooled three finasteride 1 mg trials and found it was no more effective than placebo, though it rated that evidence low quality [4]. The reviewers called for more trials of finasteride at different doses [4].
What topical finasteride has shown in women
The evidence for topical finasteride in women is limited to small studies, all in postmenopausal women.
| Study | Who | What they used | What they found |
|---|---|---|---|
| Randomized, double-blind trial, 24 weeks [5] | 30 postmenopausal women with female pattern hair loss | 0.25% finasteride + 3% minoxidil vs 3% minoxidil alone | Hair density and thickness rose in both groups; the combination was better for hair thickness. Blood DHT fell in the finasteride group [5] |
| Retrospective observational study, 52 weeks [6] | 26 postmenopausal women with female pattern hair loss | 0.25% finasteride alone, no comparison group | Hair density and thickness increased; no adverse events were recorded [6] |
These results are encouraging but early. The randomized trial had only 30 women, and the combination beat minoxidil alone on hair thickness, not on every measure [5]. The second study looked back at records, had no placebo or comparison group, and its authors describe the findings as preliminary [6]. Neither is large enough to show how often rare side effects occur.
Evidence from men
Most of what is known about topical finasteride comes from a phase III trial that randomized 458 men [8]. In that 24-week trial, topical finasteride spray increased hair count more than placebo, and peak finasteride levels in the blood were more than 100 times lower than with tablets [8]. Blood DHT fell by 34.5% with the spray compared with 55.6% with tablets [8]. That suggests less of the drug reaches the body, but not none.
What is still unknown about topical use
Honest answers matter here, because a lot is not known yet.
- Long-term results in women. The longest study in women ran 52 weeks and had no comparison group [6].
- How much reaches your bloodstream. In the women's trial, blood DHT fell, so some finasteride is absorbed [5]. How much depends on the product, and compounded products vary.
- Side effects in women. The small studies in women reported no systemic side effects or adverse events [5, 6], but they were too small to detect uncommon problems.
- Effects in women with a history of hormone-sensitive cancers. A review found general uncertainty about the safety of anti-androgens other than spironolactone in women with a history of gynecologic cancers [9].
- The right dose and formula. There is no FDA-approved topical finasteride, so there is no approved dose or labeling [2].
Side effects and the FDA's 2025 warning
In April 2025, the FDA alerted health care providers, compounders, and consumers to potential risks of compounded topical finasteride [2]. It reported receiving 32 adverse event reports between 2019 and 2024 [2]. The effects reported matched those seen with oral finasteride, including sexual side effects, anxiety, depression, suicidal thoughts, trouble thinking clearly, fatigue, and insomnia, and most reports said the effects continued after stopping [2]. Topical use can also cause skin irritation and dryness [2].
The FDA also flagged the risk of the drug transferring to other people, especially women, from skin that has been treated [2]. It advises talking with your health care provider about the risks before starting [2].
The approved oral label lists depression and suicidal thoughts and behavior among reports after approval, along with allergic reactions such as rash, itching, hives, and swelling, and breast tenderness and enlargement [1]. Most of the label's other side effects concern men. Tell your clinician if you have ever had depression, anxiety, or another mood condition before starting.
Finasteride in WarriorBabe Health hair sprays
Three of our four prescription hair sprays contain finasteride alongside minoxidil:
- Minoxidil + Tretinoin Hair Spray: minoxidil, finasteride, and tretinoin.
- Minoxidil + Ketoconazole Hair Spray: minoxidil, finasteride, latanoprost, and ketoconazole.
- Minoxidil + Fluocinolone Hair Spray: minoxidil, tretinoin, fluocinolone, and finasteride.
The fourth, the Minoxidil + Biotin Hair Spray, contains no finasteride. Compare them on our hair treatments page, and read what each ingredient is meant to do in minoxidil combination sprays.
These sprays are compounded by a licensed pharmacy under your clinician's prescription. Compounded drugs are not FDA-approved, which means the FDA does not review their safety, effectiveness, or quality before they are marketed [10]. Finasteride use in women is off-label [1]. Do not use a finasteride spray if you are pregnant or could become pregnant [1]; the tretinoin and ketoconazole sprays' product pages also say not to use them while breastfeeding. Because the drug can transfer from treated skin, keep treated skin and the bottle away from anyone who could be pregnant [2].
To see whether a hair treatment might suit you, take the 2-minute quiz. A licensed clinician reviews your health history, including pregnancy potential and mood history, and decides whether a prescription is appropriate. For the basics of hair loss, see hair thinning after menopause and minoxidil for women.
Frequently asked questions
Can women use topical finasteride?
Some clinicians prescribe it off-label, mainly for women after menopause. Finasteride's FDA label says it is not indicated for women [1], and there is no FDA-approved topical finasteride [2]. The evidence in women comes from small studies of postmenopausal women [5, 6].
Why can't you use finasteride during pregnancy?
Finasteride blocks the conversion of testosterone to DHT, which a male fetus needs for normal genital development. The FDA label says it may cause abnormalities of the external genitalia of a male fetus and is contraindicated in women who are or may become pregnant [1].
Does topical finasteride work for women?
Early evidence is mixed in strength. In a 30-woman trial, adding 0.25% finasteride to 3% minoxidil improved hair thickness more than minoxidil alone [5]. A 26-woman observational study found gains in density and thickness after 52 weeks, without a comparison group [6]. Oral finasteride 1 mg did not help postmenopausal women in a one-year trial [3].
Is topical finasteride safer than the pill?
Less of it seems to reach the body. In men, peak blood levels with a spray were more than 100 times lower than with tablets [8]. But it is still absorbed: blood DHT fell in the women's trial [5], and the FDA has received reports of side effects with compounded topical products that persisted after stopping [2].
What side effects can topical finasteride cause?
The FDA's 2025 alert described sexual side effects, anxiety, depression, suicidal thoughts, cognitive complaints, fatigue, and insomnia, plus skin irritation and dryness, in reports about compounded topical finasteride [2]. The small studies in women reported no systemic side effects, but were too small to detect uncommon ones [5, 6].
References
- Organon. Propecia (finasteride) tablets prescribing information. DailyMed, US National Library of Medicine. Revised 11/2023. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36
- US Food and Drug Administration. FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products. April 22, 2025. www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded
- Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768-776. pubmed.ncbi.nlm.nih.gov/11050579/
- van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016;(5):CD007628. pubmed.ncbi.nlm.nih.gov/27225981/
- Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147-153. pubmed.ncbi.nlm.nih.gov/30206824/
- Piraccini BM, Gupta AK, Cedirian S, et al. Topical finasteride 0.25% solution for female pattern hair loss (FPHL) in postmenopausal women: a 52-week retrospective observational study. Int J Dermatol. 2026. pubmed.ncbi.nlm.nih.gov/42876360/
- Kearney CA, Brinks AL, Lawrence CN, et al. Androgenetic alopecia in women: a narrative review of pathophysiology, clinical evaluation, and treatments. Am J Clin Dermatol. 2026;27(2):363-389. pubmed.ncbi.nlm.nih.gov/41714473/
- Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-294. pubmed.ncbi.nlm.nih.gov/34634163/
- Seyed Jafari SM, Heidemeyer K, Hunger RE, de Viragh PA. Safety of antiandrogens for the treatment of female androgenetic alopecia with respect to gynecologic malignancies. J Clin Med. 2024;13(11):3052. pubmed.ncbi.nlm.nih.gov/38892763/
- US Food and Drug Administration. Understanding the risks of compounded drugs. www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs
This article is for general information. It is not medical advice and does not replace a visit with a licensed clinician who knows your history. Do not start, stop or change a medication without talking to your clinician. If you think you are having a medical emergency, call 911.
